ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI
September 22 2023 - 8:31AM
ReShape Lifesciences Inc. (Nasdaq:
RSLS), the premier physician-led weight loss and metabolic
health solutions company, today announced that Paul F. Hickey,
President and Chief Executive Officer, and Tom Stankovich, Chief
Financial Officer, will present a company overview on Tuesday,
October 3, 2023 at 3:30 PM PT, at LD Micro’s 16th Annual Main
Event, taking place October 3-5 at the Luxe Sunset Boulevard Hotel
in Los Angeles. During the presentation, management will highlight
the company’s next-generation, anatomy-sparing, Lap-Band® program
and the nationwide, ReShapeCare™ virtual weight-management program.
ReShape Lifesciences’ management team will be
available for one-on-one meetings during the conference. To
register, please contact registration@ldmicro.com. To schedule a
meeting with management outside of the conference, contact Michael
Miller with Rx Communications at mmiller@rxir.com.
A live webcast and replay of the presentation
will be available here.
About ReShape
Lifesciences®ReShape Lifesciences® is America’s premier
weight loss and metabolic health-solutions company, offering an
integrated portfolio of proven products and services that manage
and treat obesity and metabolic disease. The FDA-approved Lap-Band®
System provides minimally invasive, long-term treatment of obesity
and is an alternative to more invasive surgical stapling procedures
such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a
virtual weight-management program that supports lifestyle changes
for all weight loss patients led by board-certified health coaches
to help them keep the weight off over time. ReShape Marketplace™ is
an online collection of quality wellness products curated for all
consumers to help them achieve their health goals. The
investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system
utilizes a proprietary vagus nerve block and stimulation technology
platform for the treatment of Type 2 diabetes and metabolic
disorders. The Obalon® balloon technology is a non-surgical,
swallowable, gas-filled intra-gastric balloon that is designed to
provide long-lasting weight loss. For more information, please
visit www.reshapelifesciences.com.
CONTACTSReShape Lifesciences Investor
Contact:Thomas StankovichChief Financial
Officer949-276-6042ir@ReShapeLifesci.com
Investor Relations Contact:Rx
Communications GroupMichael
Miller(917)-633-6086mmiller@rxir.com
ReShape Lifesciences (NASDAQ:RSLS)
Historical Stock Chart
From Jun 2024 to Jul 2024
ReShape Lifesciences (NASDAQ:RSLS)
Historical Stock Chart
From Jul 2023 to Jul 2024